Ontogenic, Immunological, and Behavioral Changes of Crack Cocaine Exposure During the Gestational Period
- PMID: 40377894
- DOI: 10.1007/s12035-025-05004-2
Ontogenic, Immunological, and Behavioral Changes of Crack Cocaine Exposure During the Gestational Period
Abstract
Crack cocaine has a high addictive power that stimulates the central nervous system (CNS), and its high consumption by women of reproductive age has generated many challenges for public health. Crack cocaine use by pregnant women has been correlated with CNS malformations, cell damage, and changes in the immune system. Our purpose was to evaluate the effects of gestational exposure to crack cocaine in pregnant rats on ectoplacental cone cells, immune organs, maternal behavior, anxiety-like phenotype, metabolites, and sensorimotor reflex development of offspring. Pregnant rats were exposed to air or crack cocaine (200 mg) from the 5th gestational day (5thGD) to the 9th GD or until the end of pregnancy. Our findings showed that gestational exposure to crack cocaine increased trophoblast cell death, associated with reduced ectoplacental cone outgrowth in vitro. Furthermore, anxiogenic-like behavior in pregnant rats and negligence in maternal care were observed after exposure to crack cocaine. The development of motor reflexes in the offspring remained unchanged. In addition, exposure to crack cocaine during pregnancy reduced the relative weight of the spleen and CD8 + T lymphocyte subsets. No changes were observed in the thymus. Finally, we observed a series of changes in the metabolites of lactating rats exposed to crack cocaine during pregnancy. Taken together, our findings provide new insight into gestational changes promoted following exposure to crack cocaine and support future clinical interventions and treatments.
Keywords: Lymphoid organ; Metabolomics; Placenta. Maternal-infant bonding; Substance of abuse.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Experiments were performed in accordance with the NIH guidelines for the care and use of laboratory animals, and with approval of the Federal University of Alagoas Animal Use Ethics Committee (Protocol #28/2021). Consent to Participate: Not applicable. Consent to Publish: Not applicable. Competing Interests: The authors declare no competing interests.
Similar articles
-
NTP Developmental and Reproductive Toxicity Technical Report on the Prenatal Development Studies of 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine (CASRN 95737-68-1) in Sprague Dawley (Hsd:Sprague Dawley® SD®) Rats and New Zealand White (Hra:NZW SPF) Rabbits: DART Report 07 [Internet].Research Triangle Park (NC): National Toxicology Program; 2022 Jan. Research Triangle Park (NC): National Toxicology Program; 2022 Jan. PMID: 35593777 Free Books & Documents. Review.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.Eur J Endocrinol. 2025 Jun 30;193(1):G1-G48. doi: 10.1093/ejendo/lvaf116. Eur J Endocrinol. 2025. PMID: 40652450
-
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD008440. doi: 10.1002/14651858.CD008440. Cochrane Database Syst Rev. 2010. PMID: 20238370 Free PMC article.
-
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2. Cochrane Database Syst Rev. 2018. PMID: 30039871 Free PMC article.
References
-
- Harzke AJ, Williams ML, Bowen AM (2009) Binge use of crack cocaine and sexual risk behaviors among African-American. HIV-positive users AIDS Behav 13:1106. https://doi.org/10.1007/S10461-008-9450-9 - DOI - PubMed
-
- Kessler F, Pechansky F (2008) A contemporary psychiatric view on the crack phenomenon. Rev Psiquiatr do Rio Gd do Sul 30:96–98
-
- Bungay V, Johnson JL, Varcoe C, Boyd S (2010) Women’s health and use of crack cocaine in context: structural and “everyday” violence. Int J Drug Policy 21:321–329. https://doi.org/10.1016/j.drugpo.2009.12.008 - DOI - PubMed
-
- Hobden KL, Cunningham JA (2006) Barriers to the dissemination of four harm reduction strategies: a survey of addiction treatment providers in Ontario. Harm Reduct J 3:1–20. https://doi.org/10.1186/1477-7517-3-1 - DOI
-
- Buchanan D, Tooze JA, Shaw S et al (2006) Demographic, HIV risk behavior, and health status characteristics of “crack” cocaine injectors compared to other injection drug users in three New England cities. Drug Alcohol Depend 81:221–229. https://doi.org/10.1016/j.drugalcdep.2005.07.011 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials